Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients
TAP-144-SR (3M) is a 3-month sustained releasing injection of a super-active agonist of luteinizing hormone releasing hormone (LH-RH), leuprorelin acetate. At the Department of Urology of Gunma University Hospital, TAP-144-SR (3M) was injected once subcutaneously into 10 prostatic cancer patients wh...
| Publié dans: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 48(2002), 12 vom: 28. Dez., Seite 771-9 |
|---|---|
| Auteur principal: | |
| Autres auteurs: | , , , , |
| Format: | Article |
| Langue: | Japanese |
| Publié: |
2002
|
| Accès à la collection: | Hinyokika kiyo. Acta urologica Japonica |
| Sujets: | Clinical Trial English Abstract Journal Article Antineoplastic Agents, Hormonal Delayed-Action Preparations Gonadotropin-Releasing Hormone 33515-09-2 Testosterone 3XMK78S47O Leuprolide |